JNJ•benzinga•
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Summary
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2024 by benzinga